Clinical Trials Arena on MSN
Wave Life Sciences’ obesity siRNA shows “once or twice-yearly” potential
In a Phase I trial, biomarkers seem to suggest the potential for a dosing administered once or twice a year of Wave’s siRNA ...
GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...
Pharmaceutical Technology on MSN
GSK forges pact with Empirico for respiratory siRNA in $745m deal
GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avecia, Inc. a leading contract development and ...
EMA grants Orphan Drug Designation to Ribo’s siRNA therapeutic RBD1016 for Hepatitis Delta Virus infection: Beijing, China Saturday, October 25, 2025, 17:00 Hrs [IST] Suzhou Rib ...
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
Codexis, Inc. recently presented data at the TIDES USA annual meeting, showcasing their ECO Synthesis platform's effectiveness in manufacturing siRNA therapeutics. Their findings emphasized reduced ...
EINPresswire/ -- According to DataM Intelligence, the RNAi Therapeutics Market will grow from USD 2.60 billion in 2024 to USD 8.80 billion by 2033, expanding at a robust CAGR of 14.6% between 2025 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback